FibroBiologics Appoints Retired NASA Astronaut Kate Rubins, Ph.D. to Board of Directors

FibroBiologics has elevated Kate Rubins, Ph.D. from its Scientific Advisory Board to its Board of Directors, a move that brings a microbiologist and genomics scientist with direct ISS research experience into formal governance of a clinical-stage cell therapy program. For scientific and regulatory leads tracking fibroblast-based therapeutics, the appointment signals a deliberate effort to anchor board-level oversight in translational biology rather than commercial or financial expertise alone.

Dr. Rubins joined the company's Scientific Advisory Board in 2022 and has since maintained proximity to FibroBiologics' fibroblast pipeline, which spans wound healing, multiple sclerosis, disc degeneration, psoriasis, and oncology. The company holds more than 270 issued and pending patents across those clinical pathways. Her transition to the board formalises an advisory relationship that CEO Pete O'Heeron described as grounded in firsthand understanding of how the human body adapts and heals under physiological stress.

The scientific credentials underpinning the appointment are substantive. Prior to her 16-year NASA career, Dr. Rubins led infectious disease immunology research as a Principal Investigator at the Whitehead Institute for Biomedical Research at MIT. During her first ISS mission, she became the first person to sequence DNA in space, a methodological advance with direct relevance to microbial identification and in-field diagnostics. She retired from NASA in 2025 and was elected to the National Academy of Medicine the same year. She currently serves as Founding Director of the Trivedi Institute for Space and Global Biomedicine at the University of Pittsburgh School of Medicine.

For development teams advancing cell therapy candidates through IND-enabling studies and early-phase clinical work, board composition increasingly shapes the scientific rigour applied to program prioritisation and risk governance. A director with hands-on molecular biology and genomics experience, particularly one familiar with research conducted under resource-constrained and high-consequence conditions, adds a layer of scientific scrutiny that complements standard regulatory and commercial board functions.

FibroBiologics' next measurable checkpoint will be clinical data readouts from its fibroblast pipeline, against which Dr. Rubins' contribution to scientific strategy will begin to be assessed.

Source: FibroBiologics, Inc. via PR Newswire, 9 July 2026.